- ISIN
- US74347R2141
- CUSIP
- 74347R214
- Issuer
- ProShares
- Inception Date
- Apr 7, 2010
- Region
- North America (U.S.)
- Category
- Leveraged Equities
- Leveraged
- 2x
- Index Tracked
- NASDAQ Biotechnology Index (200%)
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $74M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BIB Performance Chart
ProShares Ultra Nasdaq Biotechnology (BIB) is up 10.3% since the beginning of the year. BIB is currently trading at $88 per share. Investors who bought $1,000 worth of BIB shares 5 years ago would now be looking at an investment worth $967.
Loading charts...
Returns By Period
ProShares Ultra Nasdaq Biotechnology (BIB) has returned 10.33% so far this year and 95.42% over the past 12 months. Over the last ten years, BIB has returned 9.50% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
ProShares Ultra Nasdaq Biotechnology
- 1D
- 3.51%
- 1M
- 7.37%
- YTD
- 10.33%
- 6M
- 5.76%
- 1Y
- 95.42%
- 3Y*
- 18.87%
- 5Y*
- -0.66%
- 10Y*
- 9.50%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BIB Monthly Returns History
Based on dividend-adjusted daily data since Apr 8, 2010, BIB's average daily return is +0.11%, while the average monthly return is +1.97%. At this rate, an investment would double in approximately 3.0 years.
Historically, 56% of months were positive and 44% were negative. The best month was Apr 2020 with a return of +30.8%, while the worst month was Jan 2016 at -38.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, BIB closed higher 53% of trading days. The best single day was Nov 9, 2016 with a return of +18.4%, while the worst single day was Mar 16, 2020 at -19.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.19% | 6.05% | -7.53% | 0.14% | 3.64% | 4.04% | 10.33% | ||||||
| 2025 | 9.81% | -1.13% | -12.18% | -1.49% | -9.36% | 6.88% | 10.20% | 9.47% | 8.13% | 20.06% | 17.01% | -4.51% | 59.21% |
| 2024 | 0.11% | 1.21% | -0.38% | -12.32% | 11.18% | 6.11% | 12.72% | 0.86% | -5.14% | -5.64% | -1.05% | -14.24% | -9.84% |
| 2023 | 6.78% | -13.34% | 1.48% | 2.55% | -5.96% | -0.44% | 1.88% | -1.25% | -8.35% | -13.34% | 9.12% | 25.86% | -1.06% |
| 2022 | -23.24% | -8.09% | 8.39% | -19.39% | -3.68% | 0.44% | 7.92% | -2.99% | -5.90% | 17.27% | 10.93% | -6.89% | -28.85% |
| 2021 | 12.28% | -5.21% | -8.99% | 5.81% | -4.41% | 16.52% | -1.05% | 7.85% | -9.73% | -4.17% | -7.71% | -3.38% | -6.02% |
Benchmark Metrics
ProShares Ultra Nasdaq Biotechnology has an annualized alpha of 2.96%, beta of 1.85, and R2 of 0.46 versus S&P 500 Index. Calculated based on daily prices since April 08, 2010.
- This ETF captured 212.09% of S&P 500 Index gains and 172.15% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.46 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 2.96%
- Beta
- 1.85
- R²
- 0.46
- Upside Capture
- 212.09%
- Downside Capture
- 172.15%
Expense Ratio
BIB has a high expense ratio of 0.95%, indicating above-average management fees.
Return for Risk
Risk / Return Rank
BIB ranks 76 for risk / return — better than 76% of ETFs on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.35 | ||
| Sortino ratioReturn per unit of downside risk | +0.21 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.37 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 5.67 | 2.78 | +2.89 |
| Martin ratioReturn relative to average drawdown | 17.31 | 12.44 | +4.87 |
Dividends
Dividend History
ProShares Ultra Nasdaq Biotechnology provided a 0.56% dividend yield over the last twelve months, with an annual payout of $0.49 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Dividend | $0.49 | $0.62 | $0.85 | $0.04 | $0.02 |
Dividend yield | 0.56% | 0.77% | 1.69% | 0.07% | 0.03% |
Monthly Dividends
The table displays the monthly dividend distributions for ProShares Ultra Nasdaq Biotechnology. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.01 | ||||||
| 2025 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.17 | $0.00 | $0.00 | $0.18 | $0.00 | $0.00 | $0.13 | $0.62 |
| 2024 | $0.00 | $0.00 | $0.04 | $0.00 | $0.00 | $0.26 | $0.00 | $0.00 | $0.15 | $0.00 | $0.00 | $0.40 | $0.85 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.04 | $0.04 |
| 2022 | $0.02 | $0.02 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ProShares Ultra Nasdaq Biotechnology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ProShares Ultra Nasdaq Biotechnology was 67.24%, occurring on Jun 27, 2016. Recovery took 1152 trading sessions.
The current ProShares Ultra Nasdaq Biotechnology drawdown is 18.88%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2016 bear market2016 | -67.24%Jun 2016 | 11mo 12d | 4y 7mo | 5y 6moJul 2015 - Jan 2021 |
2025 selloff2025 | -66.20%Apr 2025 | 4y 1mo | — | 5y 4moFeb 2021 - now |
2011 bear market2011 | -40.88%Aug 2011 | 2mo 29d | 5mo 11d | 8mo 10dMay 2011 - Jan 2012 |
2014 bear market2014 | -39.01%Apr 2014 | 1mo 14d | 5mo 16d | 7moFeb 2014 - Sep 2014 |
2010 bear market2010 | -36.30%Jul 2010 | 2mo 16d | 5mo 19d | 8mo 5dApr 2010 - Dec 2010 |
Drawdown Indicators
| BIB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -56.78% | -10.46% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -9.10% | -7.82% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | -18.90% | -26.40% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -25.43% | -40.43% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -33.92% | -32.28% |
Current DrawdownCurrent decline from peak | -18.88% | -1.80% | -17.08% |
Average DrawdownAverage peak-to-trough decline | -32.71% | -10.71% | -22.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.53% | 2.03% | +3.50% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with BIB
Add ProShares Ultra Nasdaq Biotechnology to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BIB